2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes
2009
Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease
Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP. Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease. Arthritis & Rheumatism 2009, 60: 2183-2192. PMID: 19565490, PMCID: PMC2710404, DOI: 10.1002/art.24631.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseMultiplex enzyme-linked immunosorbent assayUsual interstitial pneumoniaC-reactive proteinAntibody-positive individualsEnzyme-linked immunosorbent assayInterstitial pneumoniaSerum levelsLung diseaseLarge cohortBiomarker assessmentIncidence of ILDMyositis-associated interstitial lung diseaseAnti-Jo-1 antibodyPulmonary function test resultsOpen lung biopsyNonspecific interstitial pneumoniaSerum inflammation markersSubset of patientsElevated serum levelsFunction test resultsIdiopathic pulmonary fibrosisDifferent patient subgroupsComputed tomography scanInducible chemokines CXCL9